Trials / Recruiting
RecruitingNCT07465965
A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic (PK) of Single-dose Administration of Semaglutide Nasal Spray (WL1006) in Adult Overweight or Obese Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Shanghai World Leader Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The specific aim of this study is to examine the Safety, Tolerability and Pharmacokinetic of Semaglutide Nasal Spray compared with placebo and positive control in Adult Overweight or Obese Participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Semaglutide Nasal Spray | WL1006 |
| DRUG | Placebo | WL1006 |
| DRUG | Semaglutide Injection | Wegovy® |
Timeline
- Start date
- 2026-03-02
- Primary completion
- 2026-08-21
- Completion
- 2026-08-30
- First posted
- 2026-03-12
- Last updated
- 2026-03-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07465965. Inclusion in this directory is not an endorsement.